ArticleScientific reports2025
Anoikis-related biomarkers PARP1 and SDCBP as diagnostic and therapeutic targets for asthma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to explore the association between anoikis-related genes (ARGs) and asthma. The dataset GSE143303 for asthma were sourced from the GEO database, while ARGs were retrieved from the Harmonizome web portal and the GeneCards database. Differentially expressed genes (DEGs) identification and GO, KEGG enrichment analysis were performed to reveal potential biological pathways. To identify hub anoikis-related DEGs (hub ARDEGs), we employed WGCNA and machine learning methods including LASSO and Random Forest. Additionally, we constructed risk prediction nomogram model and ROC curves to evaluate the asthma diagnostic value of hub ARDEGs. SsGSEA immune infiltration analysis was used to analyze the role of hub ARDEGs in the asthma immune microenvironment. Finally, miRNAs and transcription factors (TFs) interacting with these hub ARDEGs were investigated. DEGs of ARGs between asthma and healthy controls, along with WGCNA, led to the identification of six ARDEGs. GO and KEGG analyses revealed that these ARDEGs were primarily involved in the apoptotic signaling pathway and adherens junctions. Machine learning methods further narrowed down the six ARDEGs to two hub ARDEGs: PARP1 and SDCBP, which were significantly upregulated in asthma and validated using the GSE147878 and experimental models. Based on these two hub ARDEGs, a risk prediction model for asthma was developed, demonstrating strong diagnostic potential and tissue specificity in endobronchial biopsies. Immune analysis revealed variations in immune cell infiltration within asthma samples correlated with hub ARDEGs. Additionally, the miRNA-TF-mRNA interaction network of hub ARDEGs highlights the complexity of the regulatory process. The process of anoikis, immune dysregulation, and asthma are closely interconnected. The anoikis-related biomarkers PARP1 and SDCBP may serve as diagnostic markers and therapeutic targets for asthma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.